早产儿视网膜病变发病基础及抗VEGF药物治疗研究进展

早产儿视网膜病变（ｒｅｔｉｎｏｐａｔｈｙｏｆｐｒｅｍａｔｕｒｉｔｙ，ＲＯＰ）是发展中及发达国家儿童致盲的主要因素。近年来，科研人员的不断努力使得ＲＯＰ发病机理更加清晰地被认知，抗血管内皮生长因子药物治疗为ＲＯＰ患儿带来了越发光明的世界。本文综述了ＲＯＰ的发病机理、相关的血管生成因子、血小板体积、抗ＶＥＧＦ药物治疗等方面的研究进展。

Research progress on foundation and anti-VEGF drug therapy of retinopathy of prematurity

Retinopathy of prematurity ( ROP) is the major factor of blindness in children in developing and developed countries. In recent years ,persistent efforts of researchers make the pathogenesis of ROP more clearly understood , anti-VEGF drug treatment can bring ROP children more bright world. This article reviews the research progress on the pathogenesis , related angiogenesis factors , mean platelet volume and anti-VEGF drug treatment of ROP.